{"id":872065,"date":"2026-10-05T22:10:14","date_gmt":"2026-10-05T22:10:14","guid":{"rendered":"https:\/\/www.newsbeep.com\/us\/872065\/"},"modified":"2026-10-05T22:10:14","modified_gmt":"2026-10-05T22:10:14","slug":"divergent-trial-results-on-cancer-vaccines-have-field-grappling-with-hard-questions","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/us\/872065\/","title":{"rendered":"Divergent trial results on cancer vaccines have field grappling with hard questions"},"content":{"rendered":"

Allison covers what hot startups are getting up to, and who\u2019s financing them. She is also co-host of the weekly biotech podcast, \u201cThe Readout Loud<\/a>.\u201d You can reach Allison on Signal at AllisonDeAngelis.01.<\/p>\n

The recent success of a late-stage mRNA cancer vaccine<\/a>, showing the drug stopped the return of melanoma, has boosted hopes that the approach can be successfully harnessed to attack other cancers.\u00a0<\/p>\n

The question now is which ones \u2014 and whether mRNA is up to the task.\u00a0<\/p>\n

Merck and Moderna reported in August that adding their mRNA cancer vaccine to an existing treatment slowed the return and spread of melanoma. The field had been waiting \u201cwith bated breath\u201d for the news on the drug, called intismeran autogene, said Karen Knudsen, the CEO of the Parker Institute for Cancer Immunotherapy, the research organization founded by tech entrepreneur Sean Parker<\/a>. The results suggested that the idea of using messenger RNA to train the immune system to attack cancer cells \u2014 an approach first devised decades ago \u2014 was ripe for further drug development.\u00a0<\/p>\n

STAT+ Exclusive Story<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\"STAT+\"\/<\/p>\n

\t\t\t\t\t
\n\t\t\t\t\t\t\"STAT+\"\/
\n\t\t\t\t\t<\/a><\/p>\n

\t\t\t\tThis article is exclusive to STAT+ subscribers
\n\t\t\t\tUnlock this article \u2014 plus daily coverage and analysis of the biotech sector \u2014 by subscribing to STAT+.<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\t\t\tIndividual plans<\/p>\n

\t\t\t\t\t\tGroup plans<\/p>\n

\t\t\t\tView All Plans<\/a><\/p>\n

\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n

\t\t\t\t\tSubscribe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Allison covers what hot startups are getting up to, and who\u2019s financing them. She is also co-host of…\n","protected":false},"author":2,"featured_media":872066,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[244,687,245,97,247,248],"class_list":["post-872065","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-biotechnology","tag-cancer","tag-drug-development","tag-health","tag-pharmaceuticals","tag-stat"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/872065","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/comments?post=872065"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/872065\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media\/872066"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media?parent=872065"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/categories?post=872065"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/tags?post=872065"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}